Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD ¿ mixed treatment comparisons of clinical efficacy

Conclusions: FF/VI 100/25 mcg was comparable with corresponding doses of FP/SAL and BUD/FORM on lung function and health status outcomes. Non-inferiority on moderate/severe exacerbation rate was not demonstrated to the same degree of confidence, though observed rates were similar. Model limitations include a weak treatment network for the exacerbation analysis and variability across the included studies. Our data support previous RCT findings suggesting that the efficacy of FF/VI 100/25 mcg on lung function and health status in COPD is comparable with twice-daily ICS/LABAs.
Source: Respiratory Research - Category: Respiratory Medicine Authors: Source Type: research